By increasing the mutation rate way beyond the sweet spot (that what's Molnupiravir does) the virus may get some desirable mutations, but won't be able to hold on to them. And if, thanks to the drug, the patient is cured, it is bad news for the virus, those who are not infected can't produce new variants.
But like antibiotics, I think this is an "all or nothing" drug. Either give maximum dose to do as much damage as possible, or don't give anything at all. Too small a dose may promote building resistance instead.
The drug works, it reduces hospitalization and mortality in people who take it, but we don't actually need it for the most part so these studies are just further confirmation of that.
And while I understand the "see what sticks" mentality, drastically increasing the mutation rate of the virus responsible for a global pandemic... seems to me like it's on the order of "maybe we start dropping nukes, that'll slow the spread".